Trial · NCT01318135
Results by group128
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 128
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID | Serious Adverse Event | 16 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID | Serious Adverse Event | 3 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID | Serious Adverse Event | 7 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID | Serious Adverse Event | 5 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID | Other Adverse Event (≥3% Frequency Threshold) | 116 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID | Other Adverse Event (≥3% Frequency Threshold) | 134 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID | Other Adverse Event (≥3% Frequency Threshold) | 108 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID | Other Adverse Event (≥3% Frequency Threshold) | 113 | participants | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID | -0.53 | Standard Deviation 0.506 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID | -0.65 | Standard Deviation 0.515 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID | -0.53 | Standard Deviation 0.486 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID | -0.59 | Standard Deviation 0.394 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID | -0.63 | Standard Deviation 0.626 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID | -0.72 | Standard Deviation 0.589 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID | -0.61 | Standard Deviation 0.576 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID | -0.71 | Standard Deviation 0.489 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 16). | Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID | -0.66 | Standard Deviation 0.685 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 16). | Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID | -0.76 | Standard Deviation 0.660 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 16). | Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID | -0.69 | Standard Deviation 0.614 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 16). | Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID | -0.78 | Standard Deviation 0.495 | percentage of Glycosylated Hemoglobin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01318135/results